Keros Therapeutics (KROS) Projected to Post Quarterly Earnings on Wednesday

by · The Markets Daily

Keros Therapeutics (NASDAQ:KROS – Get Free Report) is anticipated to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.96) per share and revenue of $14.76 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Keros Therapeutics (NASDAQ:KROS – Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. On average, analysts expect Keros Therapeutics to post ($5.27) EPS for the current fiscal year and ($6.39) EPS for the next fiscal year.

Keros Therapeutics Stock Performance

NASDAQ:KROS opened at $10.76 on Tuesday. Keros Therapeutics has a one year low of $9.69 and a one year high of $22.55. The stock has a market cap of $213.37 million, a PE ratio of -2.91 and a beta of 1.12. The stock has a 50 day moving average price of $11.27 and a 200 day moving average price of $12.10.

Keros Therapeutics declared that its board has authorized a share buyback program on Wednesday, September 9th that authorizes the company to buy back $5 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 2.3% of its shares through open market purchases. Share buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Zacks Research raised Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 27th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Keros Therapeutics in a report on Tuesday, August 4th. Wall Street Zen cut shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday. Finally, Leerink Partners dropped their price objective on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a report on Tuesday, August 4th. Four equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $20.50.

Read Our Latest Research Report on KROS

Insider Activity

In other news, insider Lorena Raquel Lerner sold 3,568 shares of Keros Therapeutics stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total transaction of $36,714.72. Following the sale, the insider owned 27,559 shares of the company’s stock, valued at approximately $283,582.11. The trade was a 11.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 5,343 shares of company stock worth $54,985. 12.60% of the stock is owned by company insiders.

Keros Therapeutics Company Profile

(Get Free Report)

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.

Read More